# Sources — Pablo Neruda

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 6, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Nobel Prize Outreach. “Pablo Neruda: Biographical.” Nobel Prize in Literature 1971. Supports that he “was born on 12 July, 1904, in the town of Parral in Chile,” that his father “was a railway employee and his mother, who died shortly after his birth, a teacher”; that his “real name is Neftalí Ricardo Reyes Basoalto” and that from 1920 he wrote “under the pen name of Pablo Neruda”; the honorary consulships of 1927 to 1935; and his election as senator and membership of the Communist Party of Chile in 1945. https://www.nobelprize.org/prizes/literature/1971/neruda/biographical/
2. Biblioteca del Congreso Nacional de Chile. “Reseña biográfica: Pablo Neruda.” Supports the birth name “Ricardo Eliecer Neftalí Reyes Basoalto,” changed to Pablo Neruda “por sentencia judicial, el 28 de diciembre de 1946”; birth in Parral on 12 July 1904 and death in Santiago on 23 September 1973; that “el 21 de enero de 1971, el Senado aprobó su nombramiento como embajador de Chile en París” and that he presented his credentials at the end of that month; that “en julio de 1971 comenzó a tener problemas de salud y fue operado de cáncer de próstata,” writing *Geografía infructuosa* during his convalescence in France; and the Nobel Prize of 21 October 1971, received in Stockholm on 10 December 1971. https://www.bcn.cl/historiapolitica/resenas_parlamentarias/wiki/Pablo_Neruda
3. Biblioteca Nacional de Chile, *Memoria Chilena*. “Pablo Neruda (1904-1973).” Supports his appointment as ambassador to France after the 1970 election, his resignation and return to Chile in November 1972, the Nobel Prize of 1971, and that on 23 September 1973, “doce días después del golpe de Estado,” he died in Santiago at the Clínica Santa María, “víctima de un cáncer de próstata.” https://www.memoriachilena.gob.cl/602/w3-article-3638.html
4. Global News (Associated Press), November 8, 2013. “Forensic tests show no poison in remains of Chilean poet Pablo Neruda.” Supports that the head of Chile's medical legal service said “no relevant chemical substances have been found that could be linked to Mr. Neruda's death” and that experts found traces of medicine used to treat cancer. https://globalnews.ca/news/956510/forensic-tests-show-no-poison-in-remains-of-chilean-poet-pablo-neruda/
5. CBS News (Associated Press), October 20, 2017. “Pablo Neruda did not die of cancer after all, experts say.” Supports that the official version was death from cachexia due to cancer, that a panel member described “the invalidity of the death certificate when it comes to cachexia as a cause of death,” that the panel could “neither exclude nor affirm the natural or violent cause,” and that the 2013 tests showed no toxic agents in his bones. https://www.cbsnews.com/news/pablo-neruda-did-not-die-of-cancer-after-all-experts-say/
6. Daley J. “Pablo Neruda did not die of cancer, raising the possibility he was murdered.” *Smithsonian Magazine*, October 25, 2017. Supports that a 16-member international panel said it was “100 percent convinced” he did not die of cancer; that “he was 69 and suffered from prostate cancer at the time of his death”; that he was taken by ambulance to the Santa María clinic, where he died; that “the official cause of death was cancer cachexia”; a panel member's statement that “there was no indication of cachexia. He was an obese man at the time of death”; and bacteria found in a molar. https://www.smithsonianmag.com/smart-news/pablo-neruda-did-not-die-cancer-raising-possibility-he-was-murdered-180966924/
7. *The Globe and Mail*, February 15, 2023. “Pablo Neruda died with toxic bacteria in his body, say forensic experts.” Supports the finding of “DNA belonging to Clostridium botulinum in a single molar and in bone fragments” sampled in 2015, and a scientist's statement that the finding is “not definitive. It doesn't tell us what happened.” https://www.theglobeandmail.com/canada/article-pablo-neruda-died-with-toxic-bacteria-in-his-body-say-forensic
8. *Hürriyet Daily News* (AFP), February 18, 2023. “Was Neruda poisoned? Probe members say inconclusive.” Supports that panel members called their results “inconclusive as to how it entered his system.” https://hurriyetdailynews.com/was-neruda-poisoned-probe-members-say-inconclusive-180958
9. VPM (NPR News, Associated Press), February 21, 2024. “Death of Chilean poet Pablo Neruda should be reinvestigated, court rules.” Supports the appeals court's order to reopen the investigation after a judge had declined in December 2023, and that cancer is listed on the death certificate. https://www.vpm.org/npr-news/2024-02-21/death-of-chilean-poet-pablo-neruda-should-be-reinvestigated-court-rules
10. HISTMED Master Roster v3. Internal project source; not treated as independent corroboration.

## Clinical guidance

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026): staging with conventional imaging and PSMA PET, treatment of metastatic hormone-sensitive disease, germline and somatic testing, and androgen deprivation monitoring. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459
2. American Urological Association and Society of Urologic Oncology. Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026. Statements read: 4 (germline testing for all patients with advanced disease; somatic testing for metastatic disease), 10 and 11 (extent of disease; high volume defined as four or more bone metastases with at least one outside the spine and pelvis, or visceral metastases, on conventional imaging), 12 and 13 (symptoms; PSA every three to six months after ADT), 14 and 15 (ADT plus an androgen pathway-directed therapy for most patients), 16 (docetaxel triplet therapy in select patients), 17 (radiotherapy to the prostate in select patients), 18 (first-generation antiandrogens only to block flare), 37 to 39 (osteoporosis risk, calcium, vitamin D, exercise, and bone-protective drugs for high fracture risk) and 40 (denosumab or zoledronic acid to prevent skeletal events in mCRPC with bone metastases). https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer
3. Lowrance W, et al. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). *J Urol* 2023;209(6):1082-1090 (PMID 37096583). https://pubmed.ncbi.nlm.nih.gov/37096583/
4. Chi KN, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer (TITAN). *N Engl J Med* 2019;381(1):13-24 (PMID 31150574). https://pubmed.ncbi.nlm.nih.gov/31150574/
5. Kyriakopoulos CE, et al. CHAARTED long-term survival analysis. *J Clin Oncol* 2018;36(11):1080-1087 (PMID 29384722): the survival benefit of docetaxel is in high-volume disease. https://pubmed.ncbi.nlm.nih.gov/29384722/
6. Parker CC, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE). *Lancet* 2018;392(10162):2353-2366 (PMID 30355464): survival benefit in low metastatic burden. https://pubmed.ncbi.nlm.nih.gov/30355464/
7. Smith MR, et al. Early zoledronic acid in castration-sensitive prostate cancer with bone metastases (CALGB 90202). *J Clin Oncol* 2014;32(11):1143-1150 (PMID 24590644): no reduction in skeletal events. https://pubmed.ncbi.nlm.nih.gov/24590644/
8. ERLEADA (apalutamide) prescribing information, DailyMed: 240 mg once daily with a GnRH analog; withhold for grade 3 or 4 or intolerable adverse reactions; rash in 26 percent (median onset 83 days, commonly managed with antihistamines and topical corticosteroids); raised TSH and hypothyroidism; falls and fractures; strong CYP3A4 induction. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5
9. Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. *CA Cancer J Clin* 2014;64(4):225-249 (PMID 24916760). https://pubmed.ncbi.nlm.nih.gov/24916760/
10. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), prostate cancer monograph (testosterone and PSA every three to six months on ADT; DXA at baseline and every one to two years, with FRAX hip risk of 3 percent or more triggering bone-protective therapy; calcium and vitamin D; yearly lipids and glucose; blood pressure every visit; hot flashes, mood, sexual function and cognition; bowel and urinary function after radiotherapy) and hypertension monograph. https://patrickrutledge.github.io/topthirty/
11. Centers for Medicare & Medicaid Services, Medicare Wellness Visits; Medicare Preventive Services reference (Aether Forge, 2026); U.S. Preventive Services Task Force: colorectal cancer (2021), statins (2022), abdominal aortic aneurysm (2019), falls prevention (2024) and hepatitis C (2020); CDC Adult Immunization Schedule by Age. https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/preventive-services/medicare-wellness-visits.html; https://patrickrutledge.github.io/preventative_services/; https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations; https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html

## Editorial resolutions

- **Sources.** The history rests on the Nobel Prize biography, the Library of the National Congress of Chile, the National Library of Chile (*Memoria Chilena*), and AP, AFP, CBS, *Smithsonian*, *Globe and Mail* and NPR reporting on the forensic investigations. The Fundación Pablo Neruda biography page was fetched but its text did not load and is not cited; the *New York Times* (paywalled) and *The Guardian* were not read; the 2023 panel's own report was not read, only reporting on it. Britannica returned an error. Wikipedia was not used.
- **Recent-death rule.** He died in 1973, so the rule does not apply; a sick visit is included.
- **Ambassador dates (correction to the brief).** The brief gave the posting to France as 1970 to 1972. The sources say he was named after the 1970 election, the Senate approved the appointment on 21 January 1971, he presented credentials at the end of January 1971, and he resigned and returned to Chile in November 1972. The record uses 1971 to 1972 (CLM-0004).
- **Prostate cancer in 1971.** Only the congressional biography dates it: health problems from July 1971 and an operation for prostate cancer, with convalescence in France (CLM-0005, certainty “probable”). Paris is not named as the place of the operation, and the type of operation, the stage, the grade and any hormone treatment are not recorded in the sources read; the record invents none of them for the history.
- **Cause of death and the poisoning dispute.** The death certificate's cause (cancer cachexia) is recorded as a documented statement (CLM-0008). The 2013 tests, the 2017 panel, the 2023 *Clostridium botulinum* finding and the 2024 reopening are each recorded as reported (CLM-0009 to CLM-0012). Whether he died of cancer, of another natural cause or of poisoning is recorded as R, certainty “disputed” (CLM-0013), taking no side. The modern episode is set two years before his death and does not foreshadow it.
- **Name and alias.** The display name is the pen name he made legal in 1946. The alias is the congressional biography's birth name, Ricardo Eliecer Neftalí Reyes Basoalto, which appears in no other record; the Nobel biography orders the given names differently (Neftalí Ricardo), and the brief's accented “Eliécer” was not found in a source read. identity.name_parts is not used because the display name splits simply. The notes call him Mr. Neruda, as the modern episode records he asked.
- **Living people and relatives.** No living person is named. His nephew, his driver, judges and scientists quoted in the news reports are not named and nothing they said is used beyond the scientists' findings. His mother appears only in the documented family history; his wife in the modern episode is unnamed, has no role in his care and is not a source of history; his health care agent is unnamed. No other figure with a record is named, so identity.historical_mentions is not used.
- **Index age and dates.** The index visit on June 1, 2026 maps to June 1, 1971, when he was 66 and ambassador in France, weeks before the health problems of July 1971. The synthetic date of birth is 1959-07-12, a shift of 55 years. The visits on June 15, July 13, August 10, September 14 and October 5, 2026 map to the same days of 1971, before the Nobel Prize was announced on October 21, 1971; he turns 67 before the third visit. The presenting pattern is urinary symptoms and bone pain with a raised PSA, recorded as a resolved problem (R97.20) at the second visit, when the diagnosis is made.
- **Care setting.** The true frame is Paris. The modern episode keeps the project's U.S. conventions: St. Posthumous Health Center, U.S. coding, and a Medicare-style annual wellness visit; his coverage is described as an international plan through his country's diplomatic service. He is cared for in Spanish, his first language, through a professional medical interpreter, with written plans in Spanish, without any claim about Chilean or Latin American patients in general.
- **Extent of disease (decision).** Metastatic hormone-sensitive prostate cancer, de novo, low volume: two bone metastases (right ilium and L5) and two pelvic nodes, no visceral disease, on CT and bone scan, with a concordant PSMA PET/CT. Chosen because bone pain with a raised PSA fits metastatic disease, and low volume lets the record teach radiotherapy to the prostate and the decision against docetaxel. High-volume disease was considered and not chosen.
- **Treatment choices.** (1) Leuprolide continuously, with apalutamide 240 mg daily started one week earlier to cover the testosterone flare (AUA statement 18 discourages first-generation antiandrogens except for flare). (2) Apalutamide rather than abiraterone (needs prednisone; hypertension and prediabetes) or enzalutamide (a reasonable alternative). (3) No docetaxel in low-volume disease (CHAARTED; AUA statement 16 limits triplets to select patients). (4) Radiotherapy to the prostate, 55 Gy in 20 fractions (STAMPEDE). (5) Germline and somatic testing, both negative (synthetic).
- **Bone-modifying agent (correction to the brief).** The brief asked for a bone-modifying agent for metastases. In hormone-sensitive disease the AUA/SUO guideline recommends denosumab or zoledronic acid at the skeletal-event doses only for castration-resistant disease with bone metastases (statement 40), and early zoledronic acid did not reduce skeletal events in CALGB 90202. The record gives denosumab 60 mg every six months, the osteoporosis dose, for his own fracture risk (FRAX hip 3.4 percent with androgen deprivation counted; AUA statement 39; CMID threshold 3 percent), after a dental examination.
- **Guideline name (correction to the brief).** The brief named an AUA/ASTRO/SUO 2023 advanced prostate cancer guideline. The 2023 amendment is titled AUA/SUO (Lowrance 2023, PMID 37096583); the AUA page now shows a 2026 amendment. Both are cited.
- **Protocol deviation.** A TSH before apalutamide was ordered at the second visit but not drawn because it was left off the laboratory requisition. The first TSH, four weeks into treatment, was normal (2.4 mIU/L); at three months it was 5.4 mIU/L with a normal free T4, so the change is attributed to apalutamide, but a true baseline was lost. Corrective action: TSH added to the apalutamide start checklist.
- **Synthetic clinical picture.** Everything in the modern episode is synthetic: the symptoms, hypertension and prediabetes, every laboratory value, the imaging, the biopsy, DXA and FRAX, the genetic results, the scores (PHQ-9, PHQ-2, IPSS, pain, Mini-Cog, AUDIT-C), medicines and outcomes. Height (178 cm) and weights (BMI about 29 to 30) are synthetic; the 2017 panel's remark that he was obese at death was not used to set them. Reference ranges are typical adult male ranges.
- **Sick visit.** A grade 2 maculopapular rash from apalutamide eight weeks into treatment, during radiotherapy (L27.0), managed with topical triamcinolone and cetirizine while apalutamide continued, as the label allows; severe reactions were excluded by examination, eosinophils and liver tests. Chosen because it follows from his treatment and insinuates no undocumented diagnosis.
- **Annual wellness visit.** A subsequent annual wellness visit at 67 (HCPCS G0439 and CPT 99497 in plain text). Judgment calls: high-dose influenza, COVID-19 and PCV20 that day, zoster deferred at his request; RSV not given (under 75 without a qualifying condition; prostate cancer on androgen deprivation was not counted as one, a point the owner may review); atorvastatin 20 mg for a pooled-cohort risk of about 17 percent; advance care planning in Spanish with an unnamed agent.
- **Focused visits.** The three chronic-care follow-ups (the consultation day, four weeks, and three months) are documented as focused visits on the CMID prostate cancer monograph, NCCN, the AUA/SUO guideline and the apalutamide label. Synthetic findings introduced: the early PSA fall to 6.2 and the three-month PSA of 0.18 ng/mL, castrate testosterone, a blood pressure rise on apalutamide treated by raising amlodipine to 10 mg, the raised TSH, mild anemia, A1c rising to 6.1 percent, and grade 1 radiotherapy effects. The one deviation is the missed baseline TSH above.
- **Consultation.** The genitourinary medical oncology referral and the consultation by Étienne Okonkwo-Lund, MD (a fictional consultant), on the day of the second visit, are **S**. The consultant answers the six referral questions in line with what the record shows afterwards: low-volume de novo mHSPC; apalutamide with leuprolide and no docetaxel; radiotherapy to the prostate; denosumab at the osteoporosis dose for fracture risk, not for skeletal events; germline and somatic testing; and the amlodipine interaction with a monitoring plan for primary care.
